Recent healthcare research has identified the rapid growth and evolution of Klebsiella pneumoniae ST307 into a ‘superbug’ that possesses dual resistance to the final thread of antibiotics and hospital disinfectants. This grim development is gradually posing an existential risk to infection control and robustly challenging existing frameworks. This article seeks to deliver a clear, detailed understanding of the issue by presenting the findings of a multicenter cross-sectional analysis study conducted on 500 K. pneumonia samples from Iranian hospitals for a period spanning 2022 through 2024.
ST307 constituted a major 30% of the samples, with a majority derived from Intensive Care Units (ICUs). A startling resistance rate was recorded in the samples, with the rates for meropenem (a last-line antibiotic for severe infections) at 60%, ciprofloxacin at 75.3%, and gentamicin at 45.3%. Notably, colistin was still found to be effective, with an 85.3% susceptibility rate.
This study serves as a stark illumination of ST307’s escalating resilience, underscored by its resistance to multiple last-line medicines and presence in sterile environments like ICUs. The samples were found to be resistant to a worrying extent against many hospital-grade disinfectants, such as chlorhexidine and benzalkonium chloride, which are integral to infection prevention practices. This raises serious questions about the efficacy of current decontamination practices and calls for an urgent reevaluation and reinforcement of the existing infection control procedures.
Furthermore, Klebsiella pneumoniae has increasingly been implicated in hospital-acquired infections such as pneumonia, bloodstream infections, and urinary tract infections, particularly in critically ill and immunocompromised patients. Its persistent presence in healthcare environments can largely be attributed to its ability to acquire resistance via mobile genetic elements. The pathogen’s ability to swiftly evolve and disseminate has led to widespread therapeutic failures, consequently escalating mortality rates.
Therefore, this article underscores the urgent necessity for comprehensive surveillance, targeted intervention strategies, and continuous genomic surveillance. Stricter antimicrobial stewardship programs and revised disinfection protocols are also crucial to effectively control the spread of this high-risk clone and ensure the efficaciousness of existing therapeutic options. Close monitoring and understanding of high-risk clonal lineages such as ST307 are vital to incorporate urgent measures in preventing and controlling hospital-acquired infections and mitigating the spread of multidrug-resistant pathogens in hospital environments.
Source: https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-025-11178-w